5 Findings From the December 2018 Issue of AJMC®
As 2018 draws to a close, the articles in the December issue of The American Journal of Managed Care® (AJMC®) touch on some of the timeliest topics of the year, including the value of innovative immuno-oncology treatments, results of practice transformation initiatives, and much more. Here are 5 findings from the research published in the issue.
As 2018 draws to a close, the articles in the December issue of The American Journal of Managed Care® (AJMC®) touch on some of the timeliest topics of the year, including the value of innovative immuno-oncology (I-O) treatments, results of practice transformation initiatives, and much more. Here are 5 findings from the research published in the issue.
1. Medicare Advantage plans try to control postacute care costs through authorization requirements
In 154 interviews with staff at Medicare Advantage (MA) plans, hospitals, and skilled nursing facilities (SNFs),
While these restrictions make financial sense for the plans, they often provoke frustration among the hospitals and SNFs. The facilities described receiving no guidance from plans on how to achieve length of stay (LOS) goals and experiencing “a burdensome process of appealing for longer LOS.” The authors wrote that SNFs may avoid working with MA plans they perceive as too authoritative, which could adversely affect patients.
2. Introducing behavioral screening in emergency setting is feasible and indicates high prevalence of symptoms
Integrating a nonclinician into emergency department (ED) idle times to screen patients for behavioral health symptoms is feasible,
The study authors noted that this screening may be valuable for reaching patients whose only contact with the healthcare system is during ED visits. “Opportunities exist in the idle times that patients experience during ED visits to expand screening to more occult behavioral health problems without disrupting workflow,” they concluded.
3. New I-O treatments yield significant value to society via survival gains
Much excitement has surrounded the clinical promise of I-O treatments, but their economic value is not well understood.
The results indicated that survival gains are estimated at $465,000 per patient with ipilimumab for melanoma and $381,000 with nivolumab for non—small cell lung cancer, using a full income of $200,000 per year. Further, pharmaceutical profits constitute 28.4% and 11.8% of total social value for ipilimumab and nivolumab, respectively. According to the authors, these findings “suggest that novel I-O treatments have strong potential to yield not only favorable prognoses but also good value.”
4. Primary care practice transformation did not alter patient experience
The study is a follow-up to one
5. Hospital Compare grades and readmission penalties send mixed messages to consumers
For instance, 92% of hospitals were graded as “no different” than the national rate for heart failure readmissions, but 86% were penalized for their overall readmissions. The authors raised concerns that these discordant systems send an ambiguous value signal and “highlight persistent uncertainty in how best to identify and link value to payment.”
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025